Forensic Analysis · Nondurable-Goods Wholesale · as of Nov 9, 2026
DataMeds Ai, Inc. (MEDS)
A forensic read on DataMeds Ai, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-38.7
Distress distance
Clean
Earnings quality
4
Forensic signals
28.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
DataMeds Ai, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -38.7, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-359.2%
FY2025
Return on invested capital.Return on invested capital is -359.2% in the latest fiscal year, against -16.3% in FY2024. After-tax operating profit was ($5M) in FY2024 and ($74M) in FY2025, with operating income at -33.9% of revenue in FY2024 and -401.7% in FY2025. The capital base behind it came down -31% across FY2024–FY2025, from $30M to $21M, so this return is struck on a smaller base than it started on.
+50.2%/yr
FY2024–FY2025
Share-count dilution.Diluted share count changed +50% over the last 1 year to FY2025 (+50.2%/yr). The count is growing — 47.3M shares in FY2024, 71.0M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~50.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~33%.
235% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 235% of revenue in FY2025 — about $0.77 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 50.2% a year across FY2024–FY2025, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
$13M
FY2025
Goodwill impairments.Took $13M of goodwill writedowns across 1 year (FY2025 ($13M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$23.3M
Revenue Growth YoY+28.7%
Net Margin-433.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from DataMeds Ai, Inc.'s actual 10-K/10-Q/8-K filings?